COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

The Efficacy and Safety of Chlorhexidine Gluconate Chip (Periochip®) in Therapy of Symptoms in Patients With Peri-implantitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01079663
Recruitment Status : Completed
First Posted : March 3, 2010
Last Update Posted : November 15, 2011
Information provided by (Responsible Party):
Dexcel Pharma Technologies Ltd.

Brief Summary:
The purpose of the study is to assess the efficacy and the safety of Chlorhexidine Gluconate chip (Periochip®) versus Placebo Chip in treatment of symptoms in patients with Peri-Implantitis.

Condition or disease Intervention/treatment Phase
Peri-implantitis Drug: Chlorhexidine 2.5 mg Drug: Placebo chip Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: The Efficacy and Safety of Chlorhexidine Gluconate Chip (Periochip®) in Therapy of Symptoms in Patients With Peri-implantitis
Study Start Date : March 2010
Actual Primary Completion Date : October 2011
Actual Study Completion Date : November 2011

Arm Intervention/treatment
Experimental: Chlorhexidine chip (Periochip®) Drug: Chlorhexidine 2.5 mg
Placebo Comparator: Placebo chip Drug: Placebo chip

Primary Outcome Measures :
  1. Mean probing pocket depth reduction

Secondary Outcome Measures :
  1. Clinical attachment levels (CAL)
  2. Bleeding on probing (BOP)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Signed and dated Informed Consent Form.
  2. Good general health.
  3. Male or female patients aged >21 years old.
  4. Availability for the 25 week duration of the study.
  5. Peri-implantitis is characterized by the presence of at least 1 implant with periodontal pockets of 6-10 mm in depth (potential target implant) demonstrating Bleeding on Probing without involving the apex of the implant and confirmed radiographically.
  6. Females of childbearing potential must be non-pregnant and non-lactating at entry and agree to use an adequate method of birth control during the study.

Exclusion Criteria:

  1. Presence of oral local mechanical factors that could (in the opinion of the Investigator) influence the outcome of the study.
  2. Presence of orthodontic appliances, or any removable appliances, that impinges on the tissues being assessed.
  3. Presence of soft or hard tissue tumours of the oral cavity.
  4. Horizontal inter implant distance ≤2 mm (if an adjacent implant exists).
  5. Selection of the following dental implant types as target implant/s: hydroxylapatite (HA) and/or Titanium Plasma-sprayed (TPS).
  6. History of allergy to Chlorhexidine.
  7. Patients treated with systemic antibiotic therapy or periodontal/mechanical/local delivery therapy within 6 weeks prior to study entry and throughout the study duration.
  8. Patients treated with non-steroidal anti-inflammatory drugs (NSAIDs) within 14 days prior to entry into the study and throughout the study duration (excluding treatment of acetylsalicylic acid ≤100 mg /day).
  9. Patients taking Phenytoin, calcium channel blockers drugs (CCBs) and/or cyclosporine, which might influence the pattern of tissue response.
  10. Presence of any of the following conditions: Type 1 diabetes, major recurrent aphtae stomatitis, abscesses and related oral pathologies.
  11. The presence of any medical or psychiatric condition or any other condition that, in the opinion of the Investigator, could affect the successful participation of the patient in the study.
  12. Patient participates in any other clinical study 30 days prior to the start of the study and throughout the study duration.
  13. Patient uses Chlorhexidine oral rinses/ mouthwashes on a regular basis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01079663

Layout table for location information
Department of Periodontology, School of Graduate Dentistry, Rambam Health Care Center
Haifa, Israel
The Oral & Maxillofacial Surgery Unit of the Tel Aviv Medical Center
Tel Aviv, Israel
Sponsors and Collaborators
Dexcel Pharma Technologies Ltd.
Layout table for additonal information
Responsible Party: Dexcel Pharma Technologies Ltd. Identifier: NCT01079663    
Other Study ID Numbers: CLI/013P
First Posted: March 3, 2010    Key Record Dates
Last Update Posted: November 15, 2011
Last Verified: November 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Periodontal Diseases
Mouth Diseases
Stomatognathic Diseases
Anti-Infective Agents, Local
Anti-Infective Agents